Leadership update of current BOT/BAL development programs

Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer

Latest News

Botensilimab/Balstilimab clinical responses in refractory sarcomas presented at ESMO 2024.

Featured Presentation

Hear from Agenus leadership at the H.C. Wainwright 26th Annual Global Investment Conference.

Recent Publications

Botensilimab/Balstilimab in patients with refractory metastatic sarcoma presented at ESMO 2024.

Spotlight on botensilimab

Agenus’ next-generation CTLA-4 antibody

Botensilimab was designed to:

Extend the curative benefits of I-O to cold tumors that do not respond to approved immunotherapies. This is achieved by optimizing T cell interactions to drive increased potency.
Expand clinical benefit in hot tumors such as melanoma, where CTLA-4 is approved, but reported results show clinical benefit in only a third of patients and long term survival in less than a quarter of patients.
Improve tolerability by reducing or eliminating side effects that cause treatment discontinuation.

Innovation in immunotherapy

What is immunotherapy for cancer?

Today, we can create drugs that empower the immune system to do its job – cure disease.

How does botensilimab work?

By modifying the Fc “tail” of the antibody, our scientists discovered that its efficacy and tolerability can be significantly enhanced.

By the numbers

Agenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics), adjuvants and vaccines (through subsidiary SaponiQx).

clinical-stage antibody programs

US patient opportunity for lead program

0 K

partnership transactions

$ 0 B

annual manufacturing capacity for botensilimab at planned Emeryville site

$ 0 B

Acceleration through partnerships

While we retain ownership in the majority of our programs, we have accelerated the development of select programs through partnerships with industry leaders. These partnerships generate capital to further support our pipeline development, and many offer optionality for future participation in development and commercialization.

Who we are

We have brought together top talent and expertise to advance our mission, building a team of employees across our offices in the US and Europe.